A pharmaceutical representative recently brought lunch to my office to present a new drug. The drug may help some patients. The food was abundant. The room was full, with excess all around, including leftovers that were eventually thrown away. None of that is unusual in American medicine.

What has become unusual, at least for me, is how hard it now is to separate the plate in front of me from the patient in front of me, the one who asks whether there is a cheaper alternative, whether the coupon will still work next month, or whether they can wait until payday to fill the prescription.

The dissonance of care

This dissonance exists in a country where the cost of medication routinely distorts care. KFF recently reported that about one in five adults have not filled a prescription because of cost, and one-third report skipping, substituting, or rationing doses.

Against that backdrop, researching the scale of the “lunch economy” is striking. A 2024 analysis of CMS Open Payments data identified more than 1.1 million industry-sponsored events for clinicians in a single year. Of those, more than 920,000 were lunches. Together, they represented $137 million in food-and-beverage spending for physicians and nurses in one year. Lunch alone accounted for nearly $73 million.

Although the usual rhetorical move is to make those numbers sound trivial compared to corporate revenues, that is not really how moral life is experienced. Patients live in a stressful reality of copays, deductibles, and refill delays. If one translates $137 million into human terms, the result is difficult to dismiss. At $10,000 per patient per year, that sum could cover 13,700 people for a year of treatment.

No serious person believes that if the lunches disappeared tomorrow, the money would flow neatly into patient subsidies; corporate budgeting does not work that way. The more sobering truth is that it would move elsewhere in the marketing apparatus. A JAMA analysis found that medical marketing rose to nearly $30 billion by 2016, with $20 billion directed at health professionals. The lunch is not the problem because it is large, but because it is revealing, one visible and very sharp edge of a much larger machine that has found a way to eat away at my conscience.

The illusion of immunity

There is a comforting rationalization that we tell ourselves: The food is incidental, the prescribing is evidence-based, and the sandwich changes nothing. But the literature does not let us rest there. A 2016 study in JAMA Internal Medicine linked Open Payments data with Medicare Part D records for nearly 280,000 physicians and found that even a single industry-sponsored meal, with a mean value under $20, was associated with higher rates of prescribing the promoted brand-name drug.

Additional systematic reviews have reached similar conclusions: Financial interactions with pharmaceutical companies are associated with increased prescribing, higher costs, or lower prescribing quality. This matters because medicine claims fiduciary seriousness. The question is whether a profession can look squarely at evidence that small gifts are not neutral and still insist they are harmless.

Professional organizations clearly acknowledge this conflict. The AMA’s Code of Medical Ethics states that physicians may not place financial interests above patient welfare and addresses gifts and conflicts of interest explicitly. The American Academy of Family Physicians went further in 2021, arguing that physicians should refuse industry gifts because high drug prices are a public health problem and physician-directed marketing sustains an unjust system.

Unfortunately, the conflicts here are layered:

• The conflict of allocation: Patients ration medication while industry feeds the prescribers.
• The conflict of influence: Physicians believe themselves immune while the data suggest otherwise.
• The conflict of appearance: Even when judgment remains intact, the scene tells a story a patient could reasonably distrust.
• The conflict of entitlement: The quiet kind that emerges when hospitality becomes so ordinary that its absence would feel strange.

The power of refusal

Then there is the conflict that is hardest for me to write about: Futility. Suppose I decline the lunch. Will the drug suddenly become affordable? No. Will the company lower the list price? Almost certainly not.

But not every meaningful refusal has to be directly effective. Some refusals matter because they clarify what one is willing to participate in. They mark a boundary and reject the moral logic of a system even when the system cannot be corrected. If a drug is genuinely valuable, perhaps it should be able to survive a hungry audience.

Refusing a lunch is not a solution to the drug pricing crisis, nor is it a grand gesture that will topple a multibillion-dollar marketing machine. It can, however, be something much smaller and more personal; an opportunity to at least pause and mindfully reflect and reassess the space between the prescriber and the patient. While every clinician must navigate these waters for themselves, for me, the choice has become clear: Lunch is no longer just a meal; it is a weight I have found too heavy to carry.

Timothy Lesaca is a psychiatrist in private practice at New Directions Mental Health in Pittsburgh, Pennsylvania, with more than forty years of experience treating children, adolescents, and adults across outpatient, inpatient, and community mental health settings. He has published in peer-reviewed and professional venues including the Patient Experience Journal, Psychiatric Times, the Allegheny County Medical Society Bulletin, and other clinical journals, with work addressing topics such as open-access scheduling, Landau-Kleffner syndrome, physician suicide, and the dynamics of contemporary medical practice. His recent writing examines issues of identity, ethical complexity, and patient–clinician relationships in modern health care. Additional information about his clinical practice and professional work is available on his website, timothylesacamd.com. His professional profile also appears on his ResearchGate profile, where further publications and details may be found.